The CDC reports that mortality rates have been declining for most serious medical conditions including heart disease and cancer - except for death from prescription opioid abuse, which has risen dramatically since 1990. According to the CDC, "this is a major public health problem that is getting worse, and getting worse rapidly." Phoenix PharmaLabs intends to bring drugs to market that will reverse that trend.
Phoenix PharmaLabs, Inc. (PPL) is a privately held, IND-stage drug discovery company focusing on the development and commercialization of new non-addictive treatments for pain and new therapies for the treatment of opiate addiction. The company was founded in 2002 with the mission to bring its new class of opioid pain therapies and addiction treatment alternatives to the Clinic. We operate using a lean, capital-efficient business model.
PPL has designed a new class of opioid drugs with unique opiate receptor characteristics never before seen. The drugs have high binding affinity at all three opiate receptors: mu, kappa and delta and relatively more balanced receptor activity than morphine and other opioids. This profile results in the first ever opiate analgesics that appear to be non-addicting and free of all significant dangerous side effects.
Extensive animal testing by the NIH demonstrated that the company's drugs provide very high levels of analgesic potency (4 to 60 times greater than morphine) without addiction liability or any serious side effects such as respiratory depression, dysphoria, constipation, vomiting, or diuresis. The drugs are orally active and inexpensive to manufacture (using PPL's patented process). They also offer very promising use for addiction therapy as a preferred substitute for methadone and buprenorphine.
We have entered into a license agreement for the China market with Aoxing Pharmaceutical Company (NYSE: AXN). Aoxing will conduct clinical trials in China and data will be provided to the United States FDA for simultaneous approval in the US. This work is being done in collaboration with the China National Institute on Drug Dependence (Beijing University).
We intend to continue to seek complimentary business relationships, out-license opportunities and/or co-development opportunities with both domestic and overseas partners as we continue to advance our drug candidates through clinical trials.
"Use of PPL opiate in the treatment of opiate addiction." ...